Cisplatin

Catalog No.S1166

Cisplatin Chemical Structure

Molecular Weight(MW): 300.05

3 Customer Reviews

  • Cell viabilities with increasing concentrations of cisplatin (CP) and doxorubicin (DOXO) under normoxic and hypoxic condition for 48 hours were determined by MTT assay. IC50 values are presented as the means ?SDs (n=4) and * denotes p<0.05.

    Cancer Res 2014 74(1), 298-308. Cisplatin purchased from Selleck.

    PLoS One 2013 8(1), e54595. Cisplatin purchased from Selleck.

  •  

    Growth inhibitory effects of Cisplatin human pancreatic cancer cells. Capan-2 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (1% FBS) containing DMSO (control) or indicated doses of Cisplatin (Selleckchem). Cell viability 72 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. 

    2013 Dr. Edita Aksamitiene from Thomas Jefferson University. Cisplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.
Features One of the most widely used and most potent chemotherapeutic agents.
Targets
DNA synthesis [1]
(Tumor cells)
In vitro

Cisplatin induces cytotoxic by interaction with DNA to form DNA adducts which activate several signal transduction pathways, including Erk, p53, p73, and MAPK, which culminates in the activation of apoptosis. [1] Cisplatin (30 mM) treated for 6 h induces an apparent activation of Erk in HeLa cells, which is sustained over the following 14 h period. Cisplatin also shows an effective antineoplastic activity by inducing tumor cells death. Cisplatin displays ability to cause renal proximal tubular cell (RPTC) apoptosis, causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively. [4] Cisplatin (800 μM) causes typical features of necrosis of RPTC after treatment for 4 hr. [5]

In vivo Cisplatin has been demonstrated to be efficient in regression tumor growth in a wide variety of animal tumors models, including head and neck cancer xenografts, cervical squamous carcinoma xenografts, testicular carcinoma xenografts, ovarian cancer xenografts, breast carcinoma xenografts, colonic carcinoma, heterotransplanted hepatoblastoma, and so on. Cisplatin (5 mg/kg) given weekly i.v. at the day 1 and 7 induces a tumor growth inhibition (GI) of 77.5% and 85.1% of the serous xenografts Ov.Ri(C) and OVCAR-3, respectively. [6]

Protocol

Cell Research:

[3]

+ Expand
  • Cell lines: Leukemia L1210/0 cells
  • Concentrations: 7 μg/mL
  • Incubation Time: 2 hours
  • Method:

    L1210/0 cells are maintained in an exponential suspension culture at 37 ℃ in a humidified atmosphere of 5% CO2 in McCoy's medium 5a (modified), supplemented with 15% calfserum, and Fungizone. L1210/0 cells are incubated in Cisplatin (7 μg/mL) for 2 hr at 37 ℃. To measure growth inhibition, the cells are centrifuged, washed once, resuspended in fresh medium at 30 × 103 to 50 × 103 cells/mL, and incubated for 3 days. Cell numbers are determined on a Coulter Counter. An aliquot of cells is diluted with an equal volume of 0.4% trypan blue. Viability is recorded as the percentage of cells that has excluded trypan blue. Cells incubated with Cisplatin as above are also diluted into 0.1% agar and allowed to grow for 2 weeks when colonies are counted.


    (Only for Reference)
Animal Research:

[6]

+ Expand
  • Animal Models: The human ovarian cancer xenografts OVCAR-3 in nude mice
  • Formulation: 0.9% NaCl solution
  • Dosages: 5 mg/kg
  • Administration: Given i.v. at day 0 (when tumors had reached a volume between 50 and 150 mm3) and day 7.
    (Only for Reference)

Solubility (25°C)

In vitro DMF 12 mg/mL (39.99 mM)
Water 0.01 mg/mL (0.03 mM)
Ethanol 0.01 mg/mL (0.03 mM)
In vivo Saline 3mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 300.05
Formula

Cl2H6N2Pt

CAS No. 15663-27-1
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01277744 Active, not recruiting Advanced Cancers|Sarcoma M.D. Anderson Cancer Center May 9, 2011 Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT00193882 Completed Esophagus Cancer Trans-Tasman Radiation Oncology Group (TROG)|National Health and Medical Research Council, Australia|Canadian Cancer Trials Group July 7, 2003 Phase 3
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Cisplatin | Cisplatin ic50 | Cisplatin price | Cisplatin cost | Cisplatin solubility dmso | Cisplatin purchase | Cisplatin manufacturer | Cisplatin research buy | Cisplatin order | Cisplatin mouse | Cisplatin chemical structure | Cisplatin mw | Cisplatin molecular weight | Cisplatin datasheet | Cisplatin supplier | Cisplatin in vitro | Cisplatin cell line | Cisplatin concentration | Cisplatin nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID